vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and TRIO-TECH INTERNATIONAL (TRT). Click either name above to swap in a different company.

TRIO-TECH INTERNATIONAL is the larger business by last-quarter revenue ($15.6M vs $14.7M, roughly 1.1× IRIDEX CORP). On growth, TRIO-TECH INTERNATIONAL posted the faster year-over-year revenue change (81.6% vs -69.7%). Over the past eight quarters, TRIO-TECH INTERNATIONAL's revenue compounded faster (22.7% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Trio-Tech International is a global provider of semiconductor testing and burn-in solutions, alongside specialized manufacturing services for electronic components. It serves clients across the semiconductor, aerospace, and consumer electronics sectors, with operational footprints spanning North America, Asia, and Europe, delivering custom reliability testing systems and related support services.

IRIX vs TRT — Head-to-Head

Bigger by revenue
TRT
TRT
1.1× larger
TRT
$15.6M
$14.7M
IRIX
Growing faster (revenue YoY)
TRT
TRT
+151.3% gap
TRT
81.6%
-69.7%
IRIX
Faster 2-yr revenue CAGR
TRT
TRT
Annualised
TRT
22.7%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IRIX
IRIX
TRT
TRT
Revenue
$14.7M
$15.6M
Net Profit
$126.0K
Gross Margin
37.2%
16.0%
Operating Margin
0.6%
Net Margin
0.8%
Revenue YoY
-69.7%
81.6%
Net Profit YoY
-75.1%
EPS (diluted)
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
TRT
TRT
Q4 25
$14.7M
$15.6M
Q3 25
$12.5M
$15.5M
Q2 25
$13.6M
$10.7M
Q1 25
$11.9M
$7.4M
Q4 24
$12.7M
$8.6M
Q3 24
$11.6M
$9.8M
Q2 24
$12.6M
$9.7M
Q1 24
$11.8M
$10.4M
Net Profit
IRIX
IRIX
TRT
TRT
Q4 25
$126.0K
Q3 25
$-1.6M
$77.0K
Q2 25
$-994.0K
$183.0K
Q1 25
$-1.7M
$-495.0K
Q4 24
$-834.0K
$507.0K
Q3 24
$-1.9M
$-236.0K
Q2 24
$-2.7M
$243.0K
Q1 24
$-3.5M
$70.0K
Gross Margin
IRIX
IRIX
TRT
TRT
Q4 25
37.2%
16.0%
Q3 25
32.1%
16.7%
Q2 25
34.5%
24.6%
Q1 25
42.5%
26.8%
Q4 24
44.0%
25.7%
Q3 24
37.3%
23.7%
Q2 24
40.7%
27.5%
Q1 24
37.9%
26.0%
Operating Margin
IRIX
IRIX
TRT
TRT
Q4 25
0.6%
Q3 25
-11.3%
0.3%
Q2 25
-6.9%
4.4%
Q1 25
-1.7%
-4.6%
Q4 24
-3.9%
-0.0%
Q3 24
-16.1%
1.4%
Q2 24
-20.9%
3.7%
Q1 24
-28.0%
0.6%
Net Margin
IRIX
IRIX
TRT
TRT
Q4 25
0.8%
Q3 25
-12.6%
0.5%
Q2 25
-7.3%
1.7%
Q1 25
-14.2%
-6.7%
Q4 24
-6.6%
5.9%
Q3 24
-16.7%
-2.4%
Q2 24
-21.2%
2.5%
Q1 24
-29.5%
0.7%
EPS (diluted)
IRIX
IRIX
TRT
TRT
Q4 25
$0.01
Q3 25
$-0.09
$0.02
Q2 25
$-0.06
$0.11
Q1 25
$-0.10
$-0.12
Q4 24
$-0.05
$0.06
Q3 24
$-0.12
$-0.06
Q2 24
$-0.16
$0.05
Q1 24
$-0.21
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
TRT
TRT
Cash + ST InvestmentsLiquidity on hand
$6.0M
$16.5M
Total DebtLower is stronger
$581.0K
Stockholders' EquityBook value
$33.5M
Total Assets
$29.2M
$45.7M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
TRT
TRT
Q4 25
$6.0M
$16.5M
Q3 25
$5.6M
$17.4M
Q2 25
$6.8M
$16.7M
Q1 25
$7.2M
$17.6M
Q4 24
$2.4M
$16.5M
Q3 24
$3.9M
$15.5M
Q2 24
$4.1M
$16.5M
Q1 24
$5.4M
$17.0M
Total Debt
IRIX
IRIX
TRT
TRT
Q4 25
$581.0K
Q3 25
$622.0K
Q2 25
$684.0K
Q1 25
$729.0K
Q4 24
$1.0M
$782.0K
Q3 24
$1.4M
$923.0K
Q2 24
$874.0K
Q1 24
$984.0K
Stockholders' Equity
IRIX
IRIX
TRT
TRT
Q4 25
$33.5M
Q3 25
$4.7M
$34.1M
Q2 25
$6.1M
$34.0M
Q1 25
$852.0K
$32.3M
Q4 24
$2.1M
$31.8M
Q3 24
$2.6M
$33.1M
Q2 24
$4.2M
$31.3M
Q1 24
$6.5M
$31.2M
Total Assets
IRIX
IRIX
TRT
TRT
Q4 25
$29.2M
$45.7M
Q3 25
$28.4M
$47.4M
Q2 25
$31.6M
$41.1M
Q1 25
$34.2M
$40.0M
Q4 24
$29.1M
$39.8M
Q3 24
$30.2M
$42.9M
Q2 24
$31.2M
$42.5M
Q1 24
$34.1M
$43.1M
Debt / Equity
IRIX
IRIX
TRT
TRT
Q4 25
0.02×
Q3 25
0.02×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.48×
0.02×
Q3 24
0.53×
0.03×
Q2 24
0.03×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
TRT
TRT
Operating Cash FlowLast quarter
$134.0K
Free Cash FlowOCF − Capex
$-152.0K
FCF MarginFCF / Revenue
-1.0%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.06×
TTM Free Cash FlowTrailing 4 quarters
$137.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
TRT
TRT
Q4 25
$134.0K
Q3 25
$-1.2M
$933.0K
Q2 25
$-397.0K
$-664.0K
Q1 25
$-1.1M
$781.0K
Q4 24
$-1.2M
$2.1M
Q3 24
$-3.1M
$-1.9M
Q2 24
$-1.3M
$199.0K
Q1 24
$-1.6M
$1.2M
Free Cash Flow
IRIX
IRIX
TRT
TRT
Q4 25
$-152.0K
Q3 25
$-1.2M
$887.0K
Q2 25
$-410.0K
$-1.2M
Q1 25
$-1.2M
$623.0K
Q4 24
$-1.2M
$1.9M
Q3 24
$-3.1M
$-1.9M
Q2 24
$-135.0K
Q1 24
$-1.7M
$1.1M
FCF Margin
IRIX
IRIX
TRT
TRT
Q4 25
-1.0%
Q3 25
-9.4%
5.7%
Q2 25
-3.0%
-11.4%
Q1 25
-9.8%
8.4%
Q4 24
-9.8%
22.4%
Q3 24
-26.5%
-19.7%
Q2 24
-1.4%
Q1 24
-14.0%
10.6%
Capex Intensity
IRIX
IRIX
TRT
TRT
Q4 25
1.8%
Q3 25
0.1%
0.3%
Q2 25
0.1%
5.2%
Q1 25
0.1%
2.1%
Q4 24
0.1%
2.1%
Q3 24
0.0%
0.7%
Q2 24
0.0%
3.4%
Q1 24
0.0%
0.5%
Cash Conversion
IRIX
IRIX
TRT
TRT
Q4 25
1.06×
Q3 25
12.12×
Q2 25
-3.63×
Q1 25
Q4 24
4.16×
Q3 24
Q2 24
0.82×
Q1 24
16.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRIX
IRIX

Segment breakdown not available.

TRT
TRT

Semiconductor Backend Solutions$12.4M79%
Industrial Electronics$3.3M21%

Related Comparisons